The best herpes test kits for 2025, according to experts
Best at-home herpes test overall
Other top at-home herpes tests we recommend for 2025
Factors to consider when choosing an at-home herpes test
How we chose the best at-home herpes test
FAQs
Meet our experts
Update, July 2, 2025: We checked all product prices and availability. Our No. 1 pick for the best at-home herpes test remains unchanged.
(back to top)
(back to top)
Choosing the right herpes test for you is a personal decision that depends on your specific needs. Before making a decision, it's a good idea to consider certain factors:
Type of test: HSV-1 is generally considered the virus responsible for oral herpes, whereas genital herpes is associated more with HSV-2. However, since genital herpes can come from either herpes virus, tests that look for both types of of the virus tend to be more accurate. On the other hand, tests that screen only for HSV-2 are typically more cost-effective.
Collection method: Herpes can be detected using a blood sample or a swab of the lesion if an outbreak is present. According to Dr. Jill Purdie, board-certified ob/gyn in Alpharetta, Ga., taking a swab of the sore itself is the most accurate type of test, but it's also more prone to user error than a blood sample. A swab sample also requires an active outbreak, whereas a blood test can determine whether or not you've been exposed to the virus even when an outbreak is not present.
Time until results: The last thing you want to do when getting an STD test is sit around and wait for the results. Certain tests offer shorter wait times, while others might take a bit longer. All the tests on this list have a turnaround time of between one and five days.
Medical support included: If you test positive, does the company offer any type of medical support? If a medical consultation is available, is it free or does it cost extra? Additionally, is treatment or a prescribing provider available?
Cost: Along with the cost of the actual test, consider whether or not there are additional fees for shipping, follow-up support or treatment options. Also, consider whether or not FSA/HSA payments are accepted.
Accuracy: For the most accurate results, look for a company that uses CAP- and CLIA-certified labs.
Privacy: Most at-home herpes tests don't accept insurance or require extensive identifying information outside of name and address, which can go a long way toward protecting your privacy. Additionally, look for a company that offers discreet packaging when shipping.
(back to top)
To find the best at-home herpes tests on the market today, we first consulted a panel of medical experts who specialize in sexual health, urology and reproductive and women's health. Our team then researched a broad range of at-home HSV tests and rated each based on cost, the type of herpes viruses tested, accuracy, collection method and turnaround time. In addition, we considered the company's reputation and follow-up support. Specifically, we looked at whether or not the option for a health care consultation or treatment was available. After compiling the data, we narrowed our list of the best herpes tests based on specific testing needs, such as turnaround time and additional medical support.
(back to top)
Herpes is primarily detected in one of two ways: through antibodies in the blood or by the presence of the virus in a lesion. Urine tests are less common but can be used in combination with another sample method to ensure accuracy.
To date, there are not any fully at-home rapid tests that can detect the herpes virus, so all "at-home" tests require you to pre-purchase the test online, then collect the sample yourself and mail it to the lab or visit a certified lab to have the sample specimen taken for you. Regardless of the option you choose, at-home herpes enable you to get tested without making an appointment with your primary care doctor.
Herpes is a virus that causes skin infections and painful sores on the body, primarily around the mouth and genital areas. Aleece Fosnight, a board-certified physician assistant specializing in sexual medicine, women's health, and urology, tells us: "There are several types of herpes including varicella-zoster, the virus responsible for chicken pox. But the herpes simplex virus — or HSV — comes in two forms:
HSV-1 mainly causes oral herpes — also known as cold sores
HSV-2 is associated with genital herpes
HSV-1 is spread through skin-to-skin contact and saliva and mainly causes oral herpes, also known as cold sores. HSV-2, on the other hand, is usually spread through sexual contact, resulting in genital herpes.
Although herpes is most contagious during an outbreak, herpes simplex 1 and 2 can also be transmitted when there are no visible sores or symptoms. Unlike most other STDs that can only be spread through bodily fluids, HSV-1 and 2 can be transmitted through close skin-to-skin contact.
"Both types of herpes can cause small, painful blisters around the site of the infection," says Dr. Rashid Bani, medical director at Your Sexual Health. Moreover, both types can infect your face or genitals. Although HSV-2 is responsible for most cases of genital herpes, you can get genital herpes from HSV-1 (and vice versa).
Painful sores or blisters are the most common symptom of herpes, Purdie tells us. With oral herpes, there is typically just one blister, whereas genital herpes often appears in a cluster. Other common signs can include:
Fever or flu-like symptoms
Headaches
Body and muscle aches
Swollen lymph nodes in the neck or groin area
Tingling, burning or itching sensation
Unusual vaginal discharge
Painful urination
It's important to note, though, that not everyone who's infected with herpes will show symptoms. In fact, most people with HSV are asymptomatic and may not even realize they have it.
You should get tested if you begin to experience symptoms or notice any sores around your genitals, says Hack. One exception would be if you've had sex with a partner who has genital herpes. In that case, it's important to remember that it can take time for your body to develop HSV antibodies. The incubation period for herpes is typically two to 12 days, but it can take even longer. In some cases, it can take up to 16 weeks or more for HSV to be detected in your blood, Fosnight says.
Our experts agree that at-home tests are generally reliable when used correctly, so it's crucial you follow the directions for sample collection exactly as stated by the company.
While the most accurate way to detect herpes is through a viral culture or PCR test via a swab of the blister or lesion, "blood tests, which look for HSV antibodies in a blood sample, can be used if you don't have an active outbreak or sore," says Hack.
If you test positive for herpes, the next step should be to consult a healthcare provider to discuss possible treatment options. While there is no cure, treatments are available to help speed up healing, prevent or shorten outbreaks and reduce the chances of spreading it to partners.
Your doctor may also advise getting retested after a positive test result, especially if you have no symptoms. "No HSV test is perfect, and false results can occur," says Hack. For example, one study found that herpes IgM testing resulted in many false positives for HSV-2 and many false negatives for HSV-1.
False negatives can occur if the infection is very new since your body hasn't developed the antibodies yet. On the other hand, false positives can occur due to cross-reactivity. Antibody tests can sometimes react to other viruses in the same family (e.g., HSV-1 or the varicella-zoster virus). In other words, you may test positive for herpes type 2 when, in fact, you only have type 1. Because of that, it's always a good idea to discuss your results and sexual history with a doctor.
(back to top)
Dr. Stephanie Hack, board-certified obstetrician and gynecologist
Dr. Jill Purdie, board-certified ob/gyn in Alpharetta, Ga.
Aleece Fosnight, a board-certified physician assistant specializing in sexual medicine
Dr. Rashid Bani, medical director at Your Sexual Health
(back to top)
Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
6 hours ago
- Business Wire
Aptar's Dual-Active Material Science Technology Simultaneously Controls Moisture and Oxygen for Pharmaceutical Drugs and Medical Devices
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution to address these degradation drivers for pharmaceutical drugs, including oral solid dose glucagon-like peptide-1 (GLP-1), medical devices and more. This new solution marks a significant material science breakthrough in the pharmaceutical industry, extending Aptar CSP Technologies' 3-Phase Activ-Polymer™ technology into new use cases where a combination of humidity and oxidation can compromise the efficacy, safety, and shelf life of sensitive oral solid dose drugs, medical devices, implantable mesh devices, microarray patches and transdermal delivery systems. 'This launch reflects years of development, engineering excellence, and a deep understanding of our customers' most pressing stability challenges,' said Badre Hammond, Vice President Commercial Operations and General Manager, Aptar CSP Technologies. 'There has never been a singular, standalone active material aimed at protecting against both oxidation and moisture-related degradation at this level of precision across multiple platforms. We're proud to offer a solution that is not only scientifically differentiated but can also be commercially validated.' Aptar's new dual-active technology can be customized for a range of product formats and development stages, from early R&D to commercial launch. Aptar's technology can help support regulatory compliance and product protection across a variety of formats, aimed at helping companies meet strict International Council for Harmonization (ICH) stability requirements while maintaining performance and integrity of sensitive drug or device components. In addition to protection technology for oral solid dose GLP-1, Aptar also offers a range of high-quality elastomeric components for GLP-1 drug products, including plungers and rigid needle shields. Pharmaceutical companies have validated Aptar's elastomeric components and are partnering with Aptar to develop injectable solutions for GLP-1. By combining digital and Aptar's patient services, Aptar offers fully integrated solutions, which helps drug manufacturers create differentiated drug delivery systems and enhance patient experiences for GLP-1 and other applications. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Aptar CSP Technologies leverages its active material science expertise to transform ideas into market opportunities, accelerate and de-risk the product development process, and provide complete solutions that improve consumers' and patients' lives. The company offers a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit and This press release contains forward-looking statements, including the potential outcomes of the 3-Phase Activ-Polymer™ technology. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as 'expects,' 'anticipates,' 'believes,' 'estimates,' 'future,' 'potential,' 'continues' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Form 10-K and Forms 10-Q. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.

Miami Herald
7 hours ago
- Miami Herald
Formerly bankrupt weight-loss company makes a comeback
When it comes to things that most concern Americans about their health, weight loss is often at the top of the list. While America doesn't have the top obesity rate in the world, it does rank high on the list. More than 45% of Americans are obese. But the issue is bigger than just in the country - the worldwide rate of adult obesity has more than doubled since 1990, per the World Health Organization. Don't miss the move: Subscribe to TheStreet's free daily newsletter Attempts to solve this problem have spawned a thriving diet industry, always promoting the next pill, diet plan, or weight-loss gimmick to those desperate to attain better health. These approaches have all propelled the U.S. weight-loss market to grow over the decades, but the birth of GLP-1 drugs such as Ozempic sent it to new heights in 2023, with a market value of $90 billion. Related: One of Oprah's favorite things prepares for Chapter 11 bankruptcy It's a profitable market, but also an overcrowded one, and trying to get people's attention and stay on the cutting edge of what appeals to consumers presents a daunting challenge that businesses must continually navigate. Now, after one of the best-known names in the industry seemed to be on the edge of extinction, it's making a turnaround that few could have predicted - and with a new focus on a long-ignored women's issue. After declaring Chapter 11 bankruptcy in May of 2025, once-giant WeightWatchers (rebranded to WW beginning in 2018) admitted its $1.5 billion in debt was too big of a burden to continue to bear. The bankruptcy process would eliminate that debt, the company said, and it expected to reemerge as a publicly traded company. "The decisive actions we're taking today, with the overwhelming support of our lenders and noteholders, will give us the flexibility to accelerate innovation, reinvest in our members, and lead with authority in a rapidly evolving weight management landscape," said CEO Tara Comonte in a release at the time. Related: WeightWatchers takes drastic step to exit bankruptcy WeightWatchers made its debut in the '60s, at a time when diet and portion control were a focus, and enjoyed many decades of success. The company also got a significant boost when Oprah partnered with it in 2015. WeightWatchers has now emerged from that bankruptcy with a new focus: helping middle-aged women struggling with all stages of menopause, from peri to post. The new program will offer access to prescription treatments such as hormone replacement therapy and also help women connect with resources for behavioral and nutritional support, WeightWatchers said. The company also named Dr. Kim Boyd as its new chief medical officer. Boyd has worked in leadership at One Medical, Calibrate, Caire, Galileo, and Nurx in the past and has co-founded or scaled multiple consumer health companies. Menopause care has been a hot topic as of late, with high-profile actresses such as Naomi Watts founding new companies to support women going through it. After Watts experienced early menopause at 36, she founded Stripes Beauty, a brand that sells products aimed at women in all stages of the life change. WW's new angle could provide the first large-scale platform for menopausal women, which could take advantage of a once-taboo topic that's slowly gained more attention in recent years. Related: Red-hot weight-loss drug stock tanks after surprise pharma giant decision The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
7 hours ago
- Yahoo
Morphic Medical obtains CE mark for obesity treatment
Morphic Medical has obtained an EU CE mark for RESET, a device designed to target the underlying cause of obesity and type 2 diabetes (T2D). The Boston-headquartered company's RESET is a novel duodenal-jejunal bypass liner (DJBL) that mimics the effect of gastric bypass surgery and is positioned as a less-invasive option for people with T2D and obesity who have not responded well to medications or require a 'bridge' ahead of bariatric surgery. Implanted endoscopically into the upper region of the small intestine and left in place for up to nine months, RESET creates a physical barrier between receptors in the intestinal wall and food. The approach has been demonstrated to improve weight reduction and metabolic conditions by enhancing natural hormones in the gut in a manner comparable to glucagon-like peptide-1 (GLP-1) agonists. A UK study conducted at the Sandwell and West Birmingham National Health Service (NHS) Trust demonstrated that RESET's use in individuals with diabetes and obesity resulted in an average weight reduction of 17.4kg at the three-year follow up after receiving the treatment, and a 1.9% reduction in blood glucose levels alongside improvements in blood pressure and cholesterol. Morphic Medical president and CEO, Joseph Virgilio commented: "This critical regulatory milestone is an important step toward delivering on our promise and accomplishing our mission to alleviate the symptoms of obesity and metabolic disorders such as T2D for patients fighting these global epidemics. 'We're excited to help patients who have failed to achieve their goals through a programme of diet, exercise, and medical management, and are looking for an alternative therapy.' RESET is currently only available for investigational use in the US. To support a regulatory filing with the US Food and Drug Administration (FDA), Morphic is currently enrolling patients in the STEP-1 RESET pivotal trial (NCT04101669). Planned for completion in 2026, STEP-1 is a multi-centre, randomised, sham-controlled trial that plans to enrol a total of 264 patients to evaluate the safety and effectiveness of RESET, as per the study's listing on "Morphic Medical obtains CE mark for obesity treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.